🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparing Intravitreal Injection Pain Scores Using Iheezo (Chloroprocaine Hcl Ophthalmic Gel 3%) Versus Subconjunctival Lidocaine (2%): A Randomized, Controlled Trial

RecruitingPhase 4Ages 18 Years - anyAllRetina Research Institute, LLC
NCT07895420 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This will be a prospective, randomized, controlled non-inferiority trial comparing the efficacy of Iheezo versus subconjunctival 2% lidocaine in reducing intravitreal injection pain scores up to 24 hours after injection.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * At least 1 previous intravitreal injection in the last 180 days from screening. Exclusion Criteria: * History of more than 13 intravitreal injections.
💊

What it tests

  • chloroprocaine HCL 3%
  • Subconjunctival Lidocaine
📍

Where

4 sites
The Retina Institute
Glen Carbon, United States
The Retina Institute
Chesterfield, United States
The Retina Institute
City of Saint Peters, United States
The Retina Institute
St Louis, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy